SCHEMBL14503577

SCHEMBL14503577

O=C(Cl)C1C(=O)NCC1c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.53
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 1/20 0.50
HTT P42858 1/20 0.50
F2RL1 P55085 7/20 0.49
HTR2A P28223 1/20 0.46
HRH1 P35367 1/20 0.46
SLC6A2 P23975 1/20 0.46
KDM4E B2RXH2 1/20 0.45
PARP3 Q9Y6F1 1/20 0.44
HDAC3 O15379 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14812210 0.86 SLC6A3 (0.51) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL14810578 0.86 SLC6A3 (0.51) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL29434443 0.86 SLC6A3 (0.51) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL2791362 0.86 SLC6A3 (0.51) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL16784599 0.86 SLC6A3 (0.51) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL14812149 0.86 SLC6A3 (0.51) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL14811014 0.86 SLC6A3 (0.51) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL30592016 0.83 F2RL1 (0.49) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL16785349 0.80 KDM4E (0.53) SLC6A3MEN1KMT2APOLBHTT
SCHEMBL29434375 0.80 KDM4E (0.53) SLC6A3MEN1KMT2APOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123508-A1 PAR2-modulating compounds and their use ACADIA PHARMACEUTICALS INC. 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123508-A1 PAR2-modulating compounds and their use F2RL1, F2R, F2RL3 SLC6A3 4323/4885MEN1 1639/4885KMT2A 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.